In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breathe Technologies: Penetrating The Ventilator Market

Executive Summary

Breathe Technologies is bringing a bit of disruption to the staid ventilator market: NIOV, a portable ventilator, can help patients breathe easier both inside and outside the hospital. But perhaps because innovation in this field isn’t common, the company is meeting resistance from some payors, most notably the Centers for Medicare and Medicaid Services, which doesn’t see the device as a ventilator but rather another form of oxygen therapy.

You may also be interested in...

Despite Setbacks, Emphysema Devices Find Funding

Minimally invasive emphysema devices have seen their ups and downs over the years, but despite technological and regulatory challenges, VCs continue to fund these devices, with investments driven by the market opportunity, huge unmet clinical need, and promising technologies.

Breathe Technologies Inc.

The developers of a miniature, wearable ventilator for people with severe respiratory disorders view their product as the iPod of ventilators. Breathe Technologies aims to commercialize the first truly ambulatory ventilator. The company believes its innovative technology will fill an unmet need for patients with severe ventilatory insufficiency, both in the hospital setting and in the home.

Devices Fill The Lung Space

Interventional pulmonology may be a specialty device market, but its diseases, including COPD, asthma and lung cancer, are enormous and growing.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts